Cargando…

The role of elagolix in the suppression of ovulation in donor oocyte cycles

OBJECTIVE: To study the clinical use of elagolix in ovarian stimulation and its effect on premature ovulation in a cohort of women undergoing oocyte donation. DESIGN: A prospective cohort study with the use of historical controls. SETTING: A private reproductive endocrinology and infertility clinic....

Descripción completa

Detalles Bibliográficos
Autores principales: Boniface, Catherine, Schnorr, Jessica N., Gray, Jeff, McLaughlin, Jessica, Cook, Heather, Slowey, Michael, Schnorr, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310952/
https://www.ncbi.nlm.nih.gov/pubmed/37398618
http://dx.doi.org/10.1016/j.xfre.2023.03.006
_version_ 1785066642736152576
author Boniface, Catherine
Schnorr, Jessica N.
Gray, Jeff
McLaughlin, Jessica
Cook, Heather
Slowey, Michael
Schnorr, John
author_facet Boniface, Catherine
Schnorr, Jessica N.
Gray, Jeff
McLaughlin, Jessica
Cook, Heather
Slowey, Michael
Schnorr, John
author_sort Boniface, Catherine
collection PubMed
description OBJECTIVE: To study the clinical use of elagolix in ovarian stimulation and its effect on premature ovulation in a cohort of women undergoing oocyte donation. DESIGN: A prospective cohort study with the use of historical controls. SETTING: A private reproductive endocrinology and infertility clinic. PATIENT(S): Seventy-five oocyte donors and 75 historical donors, aged 21–30 years, who had each passed Food and Drug Administration and American Society for Reproductive Medicine-approved oocyte donor screening. INTERVENTION(S): Administration of elagolix 200 mg orally every night at bedtime with development of a follicular size of ≥14 mm for ovulation suppression compared with ganirelix 250 μg every night at bedtime. MAIN OUTCOME MEASURE(S): Premature ovulation rate, total oocytes, mature oocytes, maximum estradiol, luteinizing hormone, and progesterone levels. RESULT(S): Oocytes were available in all retrievals because there were no instances of premature ovulation in either the elagolix or ganirelix groups. There were no statistically significant differences between the groups in baseline demographics. Both groups had the same amounts of gonadotropins consumed and days of stimulation. The average number of total oocytes was similar between the control group and elagolix group (30.55 vs. 30.31). Furthermore, the average number of mature oocytes was similar between the control and study groups (25.42 vs. 24.73). An analysis of the 580 fresh oocytes in the elagolix group and the 737 fresh oocytes in the ganirelix group showed similar outcomes with fertilization rates of 79.7% and 84.6%, respectively. Blastocyst development rates were also similar: 62.9% in the elagolix group and 57.3% in the ganirelix group. CONCLUSION(S): Compared with a historical control group using ganirelix, patients receiving elagolix demonstrated a similar number of oocytes and mature oocytes with on average 4.2 fewer injections per cycle and average per-cycle patient savings of $289.10. CLINICAL TRIAL REGISTRATION NUMBER: Western IRB Pr. No.: 20191163, April 11, 2019. First enrollment June 20, 2019.
format Online
Article
Text
id pubmed-10310952
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103109522023-07-01 The role of elagolix in the suppression of ovulation in donor oocyte cycles Boniface, Catherine Schnorr, Jessica N. Gray, Jeff McLaughlin, Jessica Cook, Heather Slowey, Michael Schnorr, John F S Rep Cohort Study OBJECTIVE: To study the clinical use of elagolix in ovarian stimulation and its effect on premature ovulation in a cohort of women undergoing oocyte donation. DESIGN: A prospective cohort study with the use of historical controls. SETTING: A private reproductive endocrinology and infertility clinic. PATIENT(S): Seventy-five oocyte donors and 75 historical donors, aged 21–30 years, who had each passed Food and Drug Administration and American Society for Reproductive Medicine-approved oocyte donor screening. INTERVENTION(S): Administration of elagolix 200 mg orally every night at bedtime with development of a follicular size of ≥14 mm for ovulation suppression compared with ganirelix 250 μg every night at bedtime. MAIN OUTCOME MEASURE(S): Premature ovulation rate, total oocytes, mature oocytes, maximum estradiol, luteinizing hormone, and progesterone levels. RESULT(S): Oocytes were available in all retrievals because there were no instances of premature ovulation in either the elagolix or ganirelix groups. There were no statistically significant differences between the groups in baseline demographics. Both groups had the same amounts of gonadotropins consumed and days of stimulation. The average number of total oocytes was similar between the control group and elagolix group (30.55 vs. 30.31). Furthermore, the average number of mature oocytes was similar between the control and study groups (25.42 vs. 24.73). An analysis of the 580 fresh oocytes in the elagolix group and the 737 fresh oocytes in the ganirelix group showed similar outcomes with fertilization rates of 79.7% and 84.6%, respectively. Blastocyst development rates were also similar: 62.9% in the elagolix group and 57.3% in the ganirelix group. CONCLUSION(S): Compared with a historical control group using ganirelix, patients receiving elagolix demonstrated a similar number of oocytes and mature oocytes with on average 4.2 fewer injections per cycle and average per-cycle patient savings of $289.10. CLINICAL TRIAL REGISTRATION NUMBER: Western IRB Pr. No.: 20191163, April 11, 2019. First enrollment June 20, 2019. Elsevier 2023-03-25 /pmc/articles/PMC10310952/ /pubmed/37398618 http://dx.doi.org/10.1016/j.xfre.2023.03.006 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Cohort Study
Boniface, Catherine
Schnorr, Jessica N.
Gray, Jeff
McLaughlin, Jessica
Cook, Heather
Slowey, Michael
Schnorr, John
The role of elagolix in the suppression of ovulation in donor oocyte cycles
title The role of elagolix in the suppression of ovulation in donor oocyte cycles
title_full The role of elagolix in the suppression of ovulation in donor oocyte cycles
title_fullStr The role of elagolix in the suppression of ovulation in donor oocyte cycles
title_full_unstemmed The role of elagolix in the suppression of ovulation in donor oocyte cycles
title_short The role of elagolix in the suppression of ovulation in donor oocyte cycles
title_sort role of elagolix in the suppression of ovulation in donor oocyte cycles
topic Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310952/
https://www.ncbi.nlm.nih.gov/pubmed/37398618
http://dx.doi.org/10.1016/j.xfre.2023.03.006
work_keys_str_mv AT bonifacecatherine theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT schnorrjessican theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT grayjeff theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT mclaughlinjessica theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT cookheather theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT sloweymichael theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT schnorrjohn theroleofelagolixinthesuppressionofovulationindonoroocytecycles
AT bonifacecatherine roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT schnorrjessican roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT grayjeff roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT mclaughlinjessica roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT cookheather roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT sloweymichael roleofelagolixinthesuppressionofovulationindonoroocytecycles
AT schnorrjohn roleofelagolixinthesuppressionofovulationindonoroocytecycles